Goldline Pharmaceutical SME IPO Soars with Over 750 Times Subscription and GMP Surpassing 35% on Final Day!
The Goldline Pharmaceutical IPO has garnered significant attention as it approaches what is shaping up to be one of the most heavily subscribed SME issues of the month. With a total offer of Rs 11.61 crore, the IPO has seen phenomenal demand, having been subscribed 781.85 times by midday on May 14, 2026. The issue opened on May 12 with a price band set between Rs 41 to Rs 43 per share, and the allotment date is scheduled for May 15, with anticipated listing on the BSE SME platform on May 19. The robust interest has principally stemmed from retail and Non-Institutional Investors (NIIs), which collectively have driven the subscription figures to staggering levels, indicating strong investor sentiment.
In the grey market, the Goldline Pharmaceutical IPO is showing promising signs with a steady grey market premium (GMP) of Rs 15, suggesting a projected listing price of approximately Rs 58. Over the past week, the GMP has fluctuated but remained resilient, signaling sustained confidence among investors. The upward trend in the GMP indicates that market participants are optimistic about the stock’s performance post-listing, which aligns with the high demand recorded during the subscription period. The data patterns further demonstrate increasing momentum, with the subscription rates rising sharply each day, particularly for the Non-Institutional Investor category, which saw a remarkable jump on the closing day.
For Indian investors, this IPO represents an intriguing opportunity in the pharma subsector, particularly given the attractive valuation metrics compared to industry peers. Goldline’s asset-light business model, focused on marketing and distribution while outsourcing manufacturing, offers potential cost advantages but also raises concerns regarding supply chain risks. Retail investors should be cognizant of the high lot size of 3,000 shares, which necessitates a minimum investment of Rs 2.58 lakh for two lots, complicating participation for smaller investors. Additionally, the lottery system for allotment, due to the overwhelming subscription, adds an element of uncertainty that investors must weigh against the possible upside of a successful listing.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova IPO team.)